CoChat

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.

Monogenic Epilepsies: Disease Mechanisms, Clinical Phenotypes, and Targeted Therapies

Open access

Abstract

A monogenic etiology can be identified in up to 40% of people with severe epilepsy. To address earlier and more appropriate treatment strategies, clinicians are required to know the implications that specific genetic causes might have on pathophysiology, natural history, comorbidities, and treatment choices. In this narrative review, we summarize concepts on the genetic epilepsies based on the underlying pathophysiologic mechanisms and present the current knowledge on treatment options based on evidence provided by controlled trials or studies with lower classification of evidence. Overall, evidence robust enough to guide antiseizure medication (ASM) choices in genetic epilepsies remains limited to the more frequent conditions for which controlled trials and observational studies have been possible. Most monogenic disorders are very rare and ASM choices for them are still based on inferences drawn from observational studies and early, often anecdotal, experiences with precision therapies. Precision medicine remains applicable to only a narrow number of patients with monogenic epilepsies and may target only part of the actual functional defects. Phenotypic heterogeneity is remarkable, and some genetic mutations activate epileptogenesis through their developmental effects, which may not be reversed postnatally. Other genes seem to have pure functional consequences on excitability, acting through either loss- or gain-of-function effects, and these may have opposite treatment implications. In addition, the functional consequences of missense mutations may be difficult to predict, making precision treatment approaches considerably more complex than estimated by deterministic interpretations. Knowledge of genetic etiologies can influence the approach to surgical treatment of focal epilepsies. Identification of germline mutations in specific genes contraindicates surgery while mutations in other genes do not. Identification, quantification, and functional characterization of specific somatic mutations before surgery using CSF liquid biopsy or after surgery in brain specimens will likely be integrated in planning surgical strategies and reintervention after a first unsuccessful surgery as initial evidence suggests that mutational load may correlate with the epileptogenic zone. Promising future directions include gene manipulation by DNA or mRNA targeting; although most are still far from clinical use, some are in early phase clinical development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000012744

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure Schematic Representation of the Disease Mechanisms Associated With Genetic Epilepsies (A) Channelopathies, mTORopathies, and metabolic conditions where there is available targeted treatment based on the established underlying pathophysiology and (B) other genetic mechanisms including alteration of transcription, DNA repair, chromatin remodeling, synaptic pathways, and noncoding expanded repeats, where there are no available precision treatments.
Figure Schematic Representation of the Disease Mechanisms Associated With Genetic Epilepsies (A) Channelopathies, mTORopathies, and metabolic conditions where there is available targeted treatment based on the established underlying pathophysiology and (B) other genetic mechanisms including alteration of transcription, DNA repair, chromatin remodeling, synaptic pathways, and noncoding expanded repeats, where there are no available precision treatments.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 60 references

Cited by

See all 108

Metadata

Authors
Guerrini, R., Balestrini, S., Wirrell, E. C., & Walker, M. C.
Affiliations
Mayo Clinic (US)
Corresponding author
Guerrini, Renzo
Venue
Neurology
Published
2021-10-26
Volume
97
Issue
17
Pages
817-831
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W3196341288
Cited by
108
References
60
Citations by year
2026: 24 · 2025: 29 · 2024: 23 · 2023: 18 · 2022: 11 · 2021: 3
FWCI
2.45
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Neurology (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • Florence Research (University of Florence) (submittedVersion)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
  • Health Sciences › Medicine › Genetics (clinical) › Tuberous Sclerosis Complex Research
Keywords
monogenic epilepsy, genetic epilepsy, antiepileptic drugs, precision medicine, epileptogenesis, loss-of-function mutations, gain-of-function mutations, missense mutations, excitability, phenotypic heterogeneity, germline mutations, somatic mutations, liquid biopsy, epilepsy surgery, mutational load, gene therapy, mRNA targeting, natural history (disease)
MeSH terms
Anticonvulsants, Epilepsy, Humans, Genetic Predisposition to Disease, Precision Medicine, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Monogenic Epilepsies: Disease Mechanisms, Clinical Phenotypes, and Targeted Therapies. https://app.cochat.ai/papers/10.1212/wnl.0000000000012744
The paper
Guerrini, R., Balestrini, S., Wirrell, E. C., & Walker, M. C. (2021). Monogenic Epilepsies: Disease Mechanisms, Clinical Phenotypes, and Targeted Therapies. Neurology. https://doi.org/10.1212/wnl.0000000000012744

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.